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Background: Pancreatic ductal adenocarcinoma, which represents 90% of pancreatic cancers, is one of the most
lethal and aggressive malignancies. Operative resection remains the only treatment providing prolonged survival,
however, recurrence of pancreatic ductal adenocarcinoma occurs in up to 80% of patients with pancreatic cancer
within 2 years of a potential curative resection. There are few reports of pancreatic carcinoma recurrence (primary
second cancer) in the remnant pancreas after pancreatectomy.
Case presentation: A 52-year-old woman underwent a distal pancreatectomy for pancreatic cancer in September
2004. Adjuvant chemotherapy was started after surgery and continued for 4 years. In March 2012, marked elevation
of DUPAN-II was observed, followed by an irregular stenotic finding in the main duct. We performed an en bloc
resection of the remnant pancreas in July 2012. Histologically, the tumor contained a second primary pancreatic
carcinoma with lymph node metastasis. At follow-up 20 months after the second operation, the patient was alive
without recurrence. Fourteen cases of resectable cancer developing in the remnant pancreas after a pancreatectomy
for cancer have been reported; a minority of these was identified as second primary tumors. Therefore, our patient’s
primary second cancer is a rare event.
Conclusion: The patient is considered to have shown a rare, unique pancreatic cancer recurrence. Persistent elevation
of a tumor marker and extensive imaging led to proper diagnosis and treatment.
Keywords: Pancreatic carcinoma, Remnant pancreas, Repeated pancreatectomyBackground
Pancreatic cancer remains one of the most difficult can-
cers to treat and has a very poor outcome. The American
Cancer Society estimates that pancreatic cancer is the
fourth leading cause of cancer mortality, with more than
40,000 new cases in 2012 [1]. The majority of patients
initially present with clinically advanced disease, and
only 10% to 15% are candidates for surgical resection.
Despite the curative intent of surgical resection, cancer
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unless otherwise stated.than 60% of patients [2,3], and 5-year overall survival is
only 12%, even with surgery [4]. The main problems facing
surgeons treating pancreatic cancer are the frequency
of late diagnosis, the lack of biomarkers that would
allow early screening, and the absence of established
radical strategies for treating recurrences. There have
been several reports of pancreatic carcinoma recurring,
or second primary lesions developing, in the remnant
pancreas after pancreatectomy [5-16]. It is occasionally
a critical issue to determine whether the tumor is a
recurrence or is a second newly developed primary cancer.
Wada et al. suggested molecular analysis and the clinico-
pathological findings are useful in discriminating between
a recurrence versus a second primary cancer [6]. Here, wel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Akabori et al. World Journal of Surgical Oncology 2014, 12:224 Page 2 of 6
http://www.wjso.com/content/12/1/224report a rare recurrence type of pancreatic cancer—a
second developed primary carcinoma more than 7 years
after the initial surgery—for which proper diagnosis
and treatment resulted in a good outcome. We also
review the associated literature.
Case presentation
In August 2004, a 52-year-old woman was referred to our
hospital because of an abnormal finding on abdominal
ultrasonography (US) and computed tomography (CT)
scan. Physical examination was unremarkable, and except
for elevation of serum levels of DUPAN-II (1200 U/mL;
normal range: 0–150 U/mL), all laboratory data were
within the normal ranges. Abdominal US, CT scan, and
magnetic resonance imaging (MRI) showed a small tumor
in the body of the pancreas. Endoscopic retrograde
cholangiopancreatography (ERCP) showed an obstruction
(10 mm) in the main duct of the pancreatic body.
With a preoperative diagnosis of ductal carcinoma of
the pancreas, distal pancreatectomy and peripancreatic
lymph node dissection were performed on September
2004. There were no abnormal findings in the head of
the pancreas during surgery, and the cut end of the
pancreas was judged to be negative for cancer, based on
intraoperative histological examination of frozen sections.
The histological diagnosis was a moderately to poorly
differentiated tubular adenocarcinoma with perineural
invasion, lymphatic and venous permeation, and retro-
peritoneal invasion (pStage IIA, pT3pN0M0 according
to the International Union against Cancer (UICC) TNM
classification [17]) (Figure 1).
The surgical margins of the resected specimen were
free of atypical or cancerous cells. The postoperative course
was uneventful, and the serum level of DUPAN-II declined
to a normal level. Even though systemic adjuvant chemo-
therapy was performed with gemcitabine hydrochloride
(1000 mg/m2 body weight once a week for 2 weeks,
followed by 1 week of rest; constituting one treatment
cycle) from October 2004 to November 2007, the serum
DUPAN-II level gradually rose to 400 U/mL after January
2007. Therefore, a recurrence of the pancreatic cancer
was suspected, but there was no evidence of recurrence
using several imaging techniques.
In January 2008, a thoracoscopic right upper lobectomy
was performed under the diagnosis of a primary lung
cancer of the right upper lobe. The histological diagnosis
was a primary adenocarcinoma of the lung, combined type
(mucinous BAC + papillary type; pStage IA, pT1pN0M0
according to the UICC TNM classification). Six years after
the initial pancreatic operation, the DUPAN-II level
had risen to 800 U/mL in the absence of clinical signs
of recurrence. In March 2012, endoscopic ultrasonography
and ERCP confirmed pancreatic cancer recurrence with an
irregular stenotic finding in the main duct of the pancreatichead and a dilated distal main duct, associated with marked
elevation of the DUPAN-II level to more than 1,400 U/mL.
Cytology of the pancreatic juice was negative for cancer
cells. Fluorodeoxyglucose positron emission tomography
(FDG-PET) reconfirmed the absence of any distant metas-
tasis or mass lesions in the remnant pancreas.
Because the patient was in good clinical condition, a
second pancreatic operation was performed in July 2012.
The remnant pancreas and peripancreatic lymph nodes
were resected, and hepaticojejunostomy and gastrojejunost-
omy were performed. Histologically, the second pancreatic
neoplasm was diagnosed as an invasive ductal carcinoma
composed of a well to moderately differentiated tubular
adenocarcinoma with no infiltration into the microvessels
(Figure 2). In situ carcinoma was detected in the main
pancreatic duct around the invasive lesion. There was
no invasion into the retropancreatic soft tissue, and the
surgical margins of the resected specimen were free of
atypical or cancerous cells. Regional lymph node metastasis
was found and was classified as pStage IIB (pT1pN1pM0)
and R0. At follow-up 9.5 years after the first operation
and 20 months after the second operation, the patient
was alive without cancer recurrence and the DUPAN-II
concentration had normalized to 140 U/mL.
Discussion
In this case, recurrent carcinoma in the remnant pancreas
was successfully removed 7 years and 10 months after
distal pancreatectomy for invasive ductal carcinoma in
the body of the pancreas.
In the literature, we found 14 cases of a resectable
cancer developing in the remnant pancreas after pan-
createctomy for cancer of the pancreas (Table 1). When
cancer is detected in the remnant organ after resection
of a tumor with curative intent, it can be difficult to
determine whether it is a recurrence of the first cancer
or a second, newly developed, primary cancer. In the 14
cases we identified in the literature (Table 1), 9 were
diagnosed as a recurrence and 5 as a second primary
tumor in the remnant pancreas (1 report did not contain
information about the origin of the second tumor).
In our patient, we could not analyze the tumor for
mutations in the ras gene, the most prevalent type of
mutation present in pancreatic cancer [18], because the
specimen from the initial surgery was not stored, but we
judged the second neoplasm to be a second primary
tumor for the following reasons. 1) The histopathological
diagnosis of the first tumor was moderately to poorly
differentiated tubular adenocarcinoma and the surgical
margins of the resected specimen were free of atypical
cells, and were sufficiently distant from the tumor. By
contrast, the second pancreatic carcinoma was a well to
moderately differentiated tubular adenocarcinoma, and
in situ carcinoma was detected in the main pancreatic
Figure 2 Abdominal computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), and histological findings
of the second pancreatic cancer. (a) Follow-up CT revealed a dilated distal pancreatic duct with no mass in the remnant pancreas. (b) Follow-up
ERP demonstrateed a stricture of the main pancreatic duct in the head of the pancreas and a markedly dilated distal pancreatic duct. (c) Histological
examination of the remnant pancreatic tumor showed a well to moderately differentiated tubular adenocarcinoma. Hematoxylin and eosin,
magnification × 400.
Figure 1 Abdominal computed tomography (CT), endoscopic retrograde cholangiopancreatography (ERCP), and histological findings
of the first pancreatic cancer. (a) Abdominal CT showed a low-density mass in the body of the pancreas. (b) ERCP demonstratedan obstruction
of the main pancreatic duct in the pancreatic body. (c) Histological examination of the resected specimen at the first operation showed a moderately
to poorly differentiated tubular adenocarcinoma. Hematoxylin and eosin, magnification × 100.
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Table 1 Summary of resectable carcinoma developing in the Remnant pancreas after pancreatectomy for pancreatic cancer






Adjuvant therapy TM elevation Mass detected
by imaging




1 Eriguchi et al. [5] 2000 67/F 88 DP/TP IA/IIB No CA19-9 + Primary 8a
2 Wada et al. [6] 2001 52/F 22 PPPD/TP IIB/- CT CA19-9 + Local 44
3 D’Amato et al. [7] 2002 44/M 40 PPPD/TP IIB/- CRT CA19-9 + NR 22a
4 Doi et al. [8] 2003 60/M 26 DP/TP IIA/IB No No + Primary 7
5 Takamatsu et al. [9] 2005 63/M 43 PD/TP IIA/IIA CT CA19-9 + Primary 10a
6 Dalla et al. [10] 2006 63/M 12 PD/TP IIA/IIA CRT CA19-9 + Local 24a
7 Miura et al. [11] 2007 72/F 29 PPPD/DP IIA/IV NR NR + Local 5
8 Tajima et al. [12] 2008 58/M 34 PPPD/TP IB/IB No CA19-9 + Local 38a
9 Koizumi et al. [13] 2010 65/M 85 PPPD/TP IA/IIB CT No + Local 10a
10 2010 67/M 25 DP/TP IA/IIB No CA19-9 + Local 8a
11 Ogino et al. [14] 2010 63/F 71 PPPD/TP IIB/IB CT CA19-9 + Local 13a
12 2010 56/M 37 PPPD/TP IIB/IA CT CA19-9 + Local 7a
13 Kinoshita et al. [15] 2012 58/F 68 PD/TP IIB/- CT CEA, CA19-9 + Primary 2a
14 Kobayashi et al. [16] 2012 58/F 38 PPPD/TP IIB/IA CT CA19-9 + Local 20a
15 Present case 2013 52/F 94 DP/TP IIA/IIB CT DUPAN-II - Primary 20a
CRT, chemoradiotherapy; CT, chemotherapy; DP, distal pancreatectoomy; NR, not reported; PD, pancreaticoduodenectomy; PPPD, pylorus-preserving pancreaticoduodenectomy; TM, tumor marker; TP,
total pancreatectomy.
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patient had lived for 7 years and 10 months after the
resection (the longest interval among the reported
cases) is also evidence that this was likely to have been
a second primary tumor. However, we cannot completely
rule out that this was a recurrence of the original cancer
and cannot definitively prove the tumor etiology. In our
patient, long-term careful follow-up with several imaging
and tumor markers provided valuable information for the
diagnosis of remnant pancreatic carcinoma.
The typical findings that lead to the detection of pan-
creatic neoplasms include a mass lesion on CT and MRI,
as well as an irregular stricture in the main pancreatic
duct and dilation of the distal pancreatic duct, seen with
ERCP and associated with the elevation of tumor marker
levels. Koizumi [13] reported that FDG-PET can provide
valuable information for the diagnosis of remnant pancre-
atic carcinoma, even when CT or MRI shows no obvious
tumor. In the previous reports (Table 1), imaging detected
mass lesions in 14 cases (93%), and 12 (86%) had elevation
of the tumor marker CA19-9 (1 report had no information
on these measures). However, our patient was unusual
because several imaging evaluations, including FDG-PET,
did not detect a mass lesion in the remnant pancreas
before the second operation (Figure 2), which made it
difficult for us to definitively diagnose recurrent pancre-
atic carcinoma. In this case, the plasma CA19-9 levels had
remained within the normal limits (data not shown),
however, the elevated serum DUPAN-II level strongly
indicated a potential malignancy, and caused us to carry
out appropriate follow-up imaging examinations. When
a serum tumor marker is elevated during the follow-up
period, several periodic imaging evaluations (US, CT,
FDG-PET, and ERCP) are necessary and useful investi-
gative techniques for early detection of recurrence in
the remnant pancreas.Conclusion
Our patient developed pancreatic cancer in the remnant
pancreas 7 years and 10 months after distal pancreatec-
tomy. The persistent elevation of a serum tumor marker,
accompanied by detailed imaging examinations, led us to
make the correct diagnosis and give appropriate treatment
with good results. Further study is needed to determine
whether pancreatectomy for a recurrent tumor that is lim-
ited to the remnant pancreas improves patient prognosis.Consent
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